<![CDATA[Takeda Pharmaceutical Company Limited 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=21133>Sun, 14 Jun 2026 20:50:07 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations]]>https://www.newswire.co.kr/newsRead.php?no=1036418Fri, 12 Jun 2026 10:51:54 +0900<![CDATA[Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results]]>https://www.newswire.co.kr/newsRead.php?no=1034387Wed, 13 May 2026 16:11:12 +0900<![CDATA[Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)]]>https://www.newswire.co.kr/newsRead.php?no=1033838Wed, 06 May 2026 16:25:00 +0900<![CDATA[다케다, 원발성 면역결핍질환 대상 TAK-881의 중추적 제2/3상 임상시험에서 긍정적인 주요 결과 발표]]>https://www.newswire.co.kr/newsRead.php?no=1033839Wed, 06 May 2026 16:25:00 +0900<![CDATA[Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care]]>https://www.newswire.co.kr/newsRead.php?no=1031272Sun, 29 Mar 2026 11:45:00 +0900<![CDATA[Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera]]>https://www.newswire.co.kr/newsRead.php?no=1029612Wed, 04 Mar 2026 11:11:15 +0900<![CDATA[Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis]]>https://www.newswire.co.kr/newsRead.php?no=1028961Fri, 20 Feb 2026 09:57:01 +0900<![CDATA[U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1]]>https://www.newswire.co.kr/newsRead.php?no=1028534Tue, 10 Feb 2026 17:30:10 +0900<![CDATA[Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead]]>https://www.newswire.co.kr/newsRead.php?no=1027836Thu, 29 Jan 2026 15:52:14 +0900<![CDATA[Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)]]>https://www.newswire.co.kr/newsRead.php?no=1026463Tue, 06 Jan 2026 09:04:17 +0900<![CDATA[Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment]]>https://www.newswire.co.kr/newsRead.php?no=1025678Thu, 18 Dec 2025 17:09:37 +0900<![CDATA[Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera]]>https://www.newswire.co.kr/newsRead.php?no=1024802Sun, 07 Dec 2025 16:00:15 +0900<![CDATA[Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy]]>https://www.newswire.co.kr/newsRead.php?no=1022555Sun, 09 Nov 2025 09:50:08 +0900<![CDATA[New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization]]>https://www.newswire.co.kr/newsRead.php?no=1022085Tue, 04 Nov 2025 08:39:39 +0900<![CDATA[Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year]]>https://www.newswire.co.kr/newsRead.php?no=1021836Thu, 30 Oct 2025 16:51:19 +0900<![CDATA[Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors]]>https://www.newswire.co.kr/newsRead.php?no=1021129Wed, 22 Oct 2025 14:50:39 +0900<![CDATA[20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries]]>https://www.newswire.co.kr/newsRead.php?no=1019369Wed, 24 Sep 2025 09:32:18 +0900<![CDATA[Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran]]>https://www.newswire.co.kr/newsRead.php?no=1018883Wed, 17 Sep 2025 08:59:17 +0900<![CDATA[Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025]]>https://www.newswire.co.kr/newsRead.php?no=1018301Mon, 08 Sep 2025 17:39:49 +0900<![CDATA[U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease]]>https://www.newswire.co.kr/newsRead.php?no=1018215Sun, 07 Sep 2025 16:11:33 +0900<![CDATA[Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression]]>https://www.newswire.co.kr/newsRead.php?no=1015850Wed, 30 Jul 2025 16:11:15 +0900<![CDATA[Takeda Receives FDA 510(k) Clearance for HyHub™ and HyHub™ Duo Devices to Simplify HYQVIA® Administration]]>https://www.newswire.co.kr/newsRead.php?no=1015456Wed, 23 Jul 2025 14:30:00 +0900<![CDATA[다케다, HyHub™ 및 HyHub™ Duo 장치에 대한 FDA 510 승인 획득해 하이큐비아® 투여 간소화]]>https://www.newswire.co.kr/newsRead.php?no=1015457Wed, 23 Jul 2025 14:30:00 +0900<![CDATA[Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1]]>https://www.newswire.co.kr/newsRead.php?no=1014893Mon, 14 Jul 2025 16:29:30 +0900<![CDATA[Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content]]>https://www.newswire.co.kr/newsRead.php?no=1014124Tue, 01 Jul 2025 14:10:00 +0900